Technology ID
TAB-4888

Comprehensive Examination of Nuclear Envelope Defects Through a Rabbit Polyclonal Antibody Targeting Human Sun1 Inner Nuclear Membrane Protein

E-Numbers
E-074-2013-0
Lead Inventor
Jeang (Estate), Kuan-teh
Lead IC
NIAID
ICs
NIAID
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Rare/Neglected Diseases
Oncology
Metabolic Disease
Infectious Disease
Immunology
Dermatology
Cardiology
Development Stages
Prototype
Research Products
Research Equipment
Antibodies

The technology at hand involves a rabbit polyclonal antibody specifically designed for the human Sun1 inner nuclear envelope protein, even though it is directed against the mouse Sun1 inner nuclear membrane protein. Sun1 is known to be an inner nuclear envelope protein, and defects in such proteins can lead to debilitating conditions like Emery-Dreifuss muscular dystrophy and Hutchinson Gilford Progeria Syndrome. Importantly, the antibody serves as a valuable tool for diagnostic and analytical studies concerning cells afflicted with nuclear envelope defects. Given the high conservation between mouse and human Sun1 proteins, this antibody offers promising applications in unraveling the mysteries of nuclear envelope-related disorders.

 

Commercial Applications
This antibody holds promise for various applications. It can aid in researching and diagnosing nuclear envelope defects in human cells, shedding light on related diseases. Its cross-species compatibility enables comparative studies, while its diagnostic potential offers clinical utility. In summary, this antibody has versatile applications in research and diagnostics, advancing our understanding and management of nuclear envelope-related disorders.

Competitive Advantages
This antibody's unique specificity for human Sun1, despite targeting mouse Sun1, offers precision in human cell research. Its cross-species compatibility facilitates versatile experiments. Its adaptability for diagnostics and analytical studies makes it a valuable tool across various research and medical applications, positioning it as a key asset for advancing nuclear envelope defect research and related disorders.
Licensing Contact: